Sernova Biotherapeutics Inc - SEOVF STOCK NEWS

Sernova Biotherapeutics (TSX: SVA) (OTCQB: SEOVF) has appointed Ross Haghighat as Chair of the Board. Haghighat brings over three decades of experience in founding, funding, and scaling technology ventures in healthcare, with expertise in driving successful innovations, strategic growth, and mergers and acquisitions in the biotechnology sector.

The company, which focuses on developing Cell Pouch bio-hybrid organ as a functional cure for Type 1 diabetes (T1D), also announced its corporate continuance from the Canada Business Corporations Act to the Business Corporations Act (British Columbia). Additionally, the company has changed its name from Sernova Corp. to Sernova Biotherapeutics Inc., while maintaining its existing ticker symbols.

Sernova Corp. (TSX: SVA, OTCQB: SEOVF, FSE/XETRA: PSH) announced the results of its annual and special general meeting held virtually on January 10, 2025. A total of 74,190,067 common shares were voted, representing 22.8% of all outstanding shares as of November 12, 2024.

Key resolutions approved include the election of six directors: Tanya Lewis (99.6% for), Bernd Muehlenweg (99.7% for), David Paterson (99.4% for), Jonathan Rigby (99.4% for), Steven Sangha (99.4% for), and Ross Haghighat (99.5% for). KPMG LLP was appointed as auditors until the next annual meeting. Other approved resolutions include the continuance as a British Columbia , adoption of new articles, alteration of the share structure to add unlimited Preferred Shares, and an increase in the maximum number of common shares reserved for stock option grants to 50,000,000.

A conditional grant of 5,500,000 options was also approved for officers under the Option Plan. Jonathan Rigby, Sernova’s President and CEO, expressed gratitude for the shareholders' support, emphasizing the company's strengthened management team, new corporate branding, and reinvigorated corporate culture.

Sernova Corp (TSX: SVA) (OTCQB: SEOVF) has rescheduled its annual general and special meeting of shareholders from January 7, 2025, to January 10, 2025, at 1:00pm ET. The postponement is due to a recent postal strike in Canada, which affected the company's ability to mail meeting materials through Canada Post to meet regulatory requirements. The record date remains November 12, 2024.

Shareholders must submit their proxies by 1:00 p.m. ET on January 8, 2025, either through TMX Trust Company, by telephone, or online. The Management Information Circular is available on Sernova's website and SEDAR+ profile.

Sernova Corp (TSX: SVA, OTCQB: SEOVF) announced key strategic initiatives, including a non-binding letter of intent with HealthGena and GOLDTRACK Ventures for 'Project REEM Ventures' to explore product development and commercialization opportunities in Saudi Arabia for type 1 diabetes treatment. The company also welcomed Dr. Robert Gabbay, former Chief Scientific and Medical Officer at the American Diabetes Association, as a clinical advisor. Sernova will host a virtual Town Hall on December 13 and hold its Annual General Meeting on January 7, 2025. The company is developing a Cell Pouch bio-hybrid organ as a potential functional cure for type 1 diabetes and thyroid disorders.

Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) has announced positive interim data from its ongoing Phase I/II clinical trial of the Cell Pouch Transplant System for type 1 diabetes (T1D). The trial shows sustained insulin independence in all 6 patients of Cohort A after islet transplantation. Notably, histological data from a patient's explanted Cell Pouch after 5+ years revealed abundant, well-vascularized, functioning islets producing insulin, glucagon, and somatostatin. The Cell Pouch demonstrated no evidence of fibrosis or degradation after long-term implantation. Sernova plans to complete Cohort B soon and initiate Cohort C with an optimized immune suppression regimen. The company is also developing iPSC-derived islet-like clusters with partner Evotec for a scalable cell source.

Sernova Corp. (TSX:SVA) (OTCQB:SEOVF), a clinical-stage biotech company focusing on regenerative medicine cell therapies, has appointed Jonathan Rigby as its new CEO. Rigby, a type 1 diabetic himself, brings extensive experience in raising capital, leading biotech companies to Nasdaq listings, and achieving strategic acquisitions. The Board believes Rigby's leadership will position Sernova to achieve its strategic milestones.

Rigby's background includes several CEO roles and board positions in biotech companies, particularly in the diabetes field. He holds a degree in biological sciences and an MBA. The appointment aims to drive Sernova's growth and realize its full potential in developing treatments for chronic diseases, including its ongoing phase 1/2a clinical trial in type 1 diabetes.

Sernova Corp. (SVA) announces FDA Orphan Drug Designation and Rare Pediatric Disease Designation for Hemophilia A program, using Cell Pouch™ with cells corrected for Factor VIII production. The designations provide tax credits, FDA fee waivers, market exclusivity, and priority review voucher benefits, aiming to impact patients globally.

Sernova Corp. announced an update on its conformal coating immune protection technology program, aiming to eliminate the need for chronic immunosuppression medications in islet cell transplantation for type 1 diabetes treatment. The update presented positive advancements in coating composition and process, including a 500% increase in production capacity and an 89% encapsulation yield. The final product contained 98% coated islets and demonstrated biocompatibility and glucose-stimulated insulin transfer. Pilot studies established optimal conditions for diabetes reversal, and release criteria for clinical manufacturing have been developed. Manufacturing of coating scale-up equipment is in progress.

Sernova Corp presents positive interim results from Phase 1/2 clinical trial investigating islet allotransplantation into Cell Pouch